In fact, PD-L1+ CD11b+ F4/80–Gr1+ neutrophils and PD-L1+ CD11b+ F4/80+ macrophages accounted for the majority of PD-L1+ leukocytes post BNT162b2-based cancer therapy. This evidence concerns the gene ITGAM and cancer.